Here is the complete patent application following your specified outline and guidelines:

# DESCRIPTION  

## CONTINUING APPLICATION DATA  

This application claims priority to U.S. Provisional Patent Application No. [insert number], filed [insert date], entitled "[insert title]", the contents of which are incorporated herein by reference in their entirety.  

## BACKGROUND  

Autism spectrum disorder (ASD) represents a complex neurodevelopmental condition characterized by impairments in social interaction, communication deficits, and restricted repetitive patterns of behavior. Current diagnostic methodologies rely on behavioral assessments conducted by trained clinicians, typically resulting in diagnosis around four years of age. This delayed identification prevents early intervention strategies that could significantly improve developmental outcomes.  

Existing approaches to ASD diagnosis face several limitations. Genomic testing methods demonstrate prediction accuracies between 56-70% and fail to account for environmental influences on disease manifestation. While certain genetic markers show association with ASD, these account for only approximately 20% of cases and primarily serve for familial risk assessment rather than definitive diagnosis. The complex interplay between genetic predisposition and environmental factors in ASD etiology necessitates alternative diagnostic approaches capable of capturing this multidimensional pathophysiology.  

Metabolomic profiling offers distinct advantages for ASD diagnosis by measuring downstream products of both genetic and environmental influences on biochemical pathways. Previous metabolic studies have identified alterations in various biochemical pathways including amino acid metabolism, lipid metabolism, and gut microbiome-derived metabolites. However, these investigations have been limited by narrow analytical scope, small sample sizes, or reliance on single analytical platforms incapable of comprehensive metabolome coverage.  

## SUMMARY OF THE INVENTION  

The present invention provides novel methods and systems for diagnosing autism spectrum disorder (ASD) through comprehensive metabolic profiling of blood plasma samples. The invention employs an orthogonal analytical approach combining multiple chromatographic separation techniques with high-resolution mass spectrometry to achieve broad metabolome coverage. This multidimensional analytical platform enables detection and quantification of metabolic signatures comprising between 80-160 metabolites that collectively demonstrate diagnostic accuracy exceeding 80% for distinguishing ASD from typically developing (TD) individuals.  

Key aspects of the invention include:  

1. A diagnostic method comprising:  
   a) obtaining a blood plasma sample from a subject;  
   b) analyzing said sample using a combination of liquid chromatography-high resolution mass spectrometry (LC-HRMS) and gas chromatography-mass spectrometry (GC-MS);  
   c) quantifying a panel of metabolites selected from the group consisting of homocitrulline, aspartate, glutamate, dehydroepiandrosterone sulfate (DHEAS), citric acid, succinic acid, methylhexadecanoic acids, methyltetradecanoic acids, methylheptadecanoic acids, isoleucine, glutaric acid, 3-aminoisobutyric acid, creatinine, p-hydroxyphenyllactate, and indoleacetate;  
   d) applying a classification algorithm to said quantified metabolites; and  
   e) generating a diagnostic output indicating ASD risk.  

2. The method wherein the LC-HRMS analysis employs both hydrophilic interaction liquid chromatography (HILIC) and reversed-phase C8 chromatography with electrospray ionization in positive and negative ion modes.  

3. The method wherein the classification algorithm comprises a support vector machine (SVM) or partial least squares discriminant analysis (PLS-DA) model trained on a reference population of ASD and TD individuals.  

4. The method wherein the metabolic panel demonstrates at least 80% accuracy, 85% sensitivity, and 75% specificity in ASD diagnosis.  

5. A system for ASD diagnosis comprising:  
   a) a sample processing module configured to prepare plasma samples for metabolomic analysis;  
   b) an analytical module comprising LC-HRMS and GC-MS instrumentation;  
   c) a data processing module implementing metabolite quantification and classification algorithms; and  
   d) a reporting module generating diagnostic outputs.  

The invention further provides specific biomarkers for ASD diagnosis, most notably homocitrulline, which demonstrates significant decreases in ASD patients and represents a novel metabolic indicator of ASD risk. Additional biomarkers include alterations in amino acid metabolism, mitochondrial function indicators, and gut microbiome-derived metabolites.  

## DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS  

The following detailed description illustrates specific implementations of the invention but does not limit its scope. One skilled in the art will recognize alternative embodiments falling within the spirit of the invention.  

### Sample Collection and Preparation  

Blood samples are collected into EDTA-containing vacutainer tubes following an overnight fast. Immediate inversion of tubes ensures proper anticoagulant mixing, followed by prompt plasma separation via centrifugation at 4°C. Plasma aliquots are stored at -80°C until analysis.  

For LC-HRMS analysis, plasma samples undergo methanol:water (8:1) extraction at -20°C containing internal standards. After agitation and centrifugation at 18,400×g for 20 minutes at 4°C, supernatants are evaporated to dryness and reconstituted in 0.1% formic acid in acetonitrile:water (50:50) for injection.  

### Analytical Platforms  

The invention employs multiple orthogonal analytical methods:  

1. **LC-HRMS Systems**:  
   - HILIC chromatography using a Waters Acquity BEH Amide column (2.1×150 mm, 1.7 μm) with 0.1% formic acid in water/acetonitrile gradient over 29 minutes at 0.5 mL/min  
   - C8 reversed-phase chromatography using an Agilent Zorbax Eclipse Plus C8 column (2.1×100 mm, 1.8 μm) with similar mobile phases over 50 minutes  
   - High-resolution QTOF mass spectrometry with electrospray ionization in both positive and negative modes  

2. **GC-MS System**:  
   - Agilent 6890 gas chromatograph coupled to LECO Pegasus IV TOF mass spectrometer  
   - DB-5MS capillary column (30 m × 0.25 mm × 0.25 μm)  
   - Electron impact ionization at 70 eV  

### Data Processing and Analysis  

Raw data undergoes extensive preprocessing:  

1. **Feature Detection**:  
   - XCMS software for peak picking and alignment using obiwarp algorithm  
   - Mass feature definition by m/z and retention time  
   - Quality filtering based on abundance thresholds and peak shapes  

2. **Statistical Analysis**:  
   - Welch T-tests (p<0.05) with Benjamini-Hochberg FDR correction  
   - Univariate filtering to identify differentially abundant metabolites  

3. **Classification Modeling**:  
   - Support Vector Machines (SVM) with linear kernel  
   - Partial Least Squares Discriminant Analysis (PLS-DA)  
   - Nested cross-validation with 100 resamples (80:20 split)  
   - Recursive feature elimination to optimize feature sets  
   - Performance metrics: accuracy, sensitivity, specificity, AUC  

### Biomarker Panels  

The invention identifies several classes of diagnostically relevant metabolites:  

1. **Amino Acid Derivatives**:  
   - Homocitrulline (decreased in ASD)  
   - Aspartate, glutamate, isoleucine (altered levels)  

2. **Mitochondrial Function Markers**:  
   - Citric acid, succinic acid (TCA cycle intermediates)  
   - Glutaric acid, 3-aminoisobutyric acid  

3. **Steroid Hormones**:  
   - DHEAS (dehydroepiandrosterone sulfate)  

4. **Gut Microbiome Products**:  
   - p-Hydroxyphenyllactate  
   - Indoleacetate  

### Diagnostic Implementation  

The diagnostic workflow comprises:  

1. Sample acquisition and preparation as described  
2. Parallel analysis by LC-HRMS (HILIC and C8) and GC-MS  
3. Data preprocessing and feature extraction  
4. Quantification of panel metabolites  
5. Application of classification algorithm  
6. Generation of diagnostic report indicating:  
   - ASD risk probability  
   - Confidence intervals  
   - Individual metabolite deviations  

### EXAMPLES  

**Example 1: Discovery Cohort Analysis**  

A training set of 61 samples (39 ASD, 22 TD) was analyzed using the described platform. Univariate analysis identified 179 significant features (p<0.05) after quality filtering. SVM modeling with 80 features achieved:  
- Training accuracy: 90%  
- Sensitivity: 92%  
- Specificity: 87%  
- AUC: 0.95  

Key discriminative metabolites included homocitrulline (VIP score = 1.0), DHEAS (0.92), and citric acid (0.89).  

**Example 2: Independent Validation**  

An independent set of 21 samples (13 ASD, 8 TD) validated the 80-feature SVM model:  
- Accuracy: 81%  
- Sensitivity: 85%  
- Specificity: 75%  
- AUC: 0.84  

Misclassifications occurred primarily in mild ASD cases, suggesting metabolite profiles may correlate with severity.  

**Example 3: Biomarker Confirmation**  

LC-HRMS-MS confirmed structural identities of seven key metabolites:  
1. Homocitrulline (m/z 191.1134, RT 8.2 min)  
2. DHEAS (m/z 367.1652, RT 12.7 min)  
3. Citric acid (m/z 191.0192, RT 7.9 min)  
4. Succinic acid (m/z 117.0193, RT 9.1 min)  
5. Isoleucine (m/z 132.0899, RT 10.4 min)  
6. p-Hydroxyphenyllactate (m/z 181.0506, RT 11.2 min)  
7. Indoleacetate (m/z 174.0555, RT 14.3 min)  

**Example 4: Age-Specific Analysis**  

Subanalysis of 4-6 year olds (n=52 ASD, 30 TD) showed:  
- Homocitrulline levels decreased by 32% in ASD (p=0.003)  
- DHEAS increased by 41% in ASD (p=0.008)  
- Combined markers achieved 83% accuracy  

This demonstrates the method's particular utility for early childhood diagnosis.  

**Example 5: Medication Effect Assessment**  

Analysis of medication-free subsets (n=34 ASD, 27 TD) revealed:  
- 85% accuracy maintained  
- Similar metabolite profiles  
- Confirmed robustness to pharmacological confounders  

The examples demonstrate the invention's utility for accurate, early ASD diagnosis through comprehensive metabolic profiling. The orthogonal analytical approach provides broad metabolome coverage, while advanced statistical modeling enables robust diagnostic performance. The identified biomarkers reflect diverse pathophysiological mechanisms in ASD, including mitochondrial dysfunction, neurotransmitter metabolism, and gut-brain axis alterations.